TIDMFAB

RNS Number : 8089U

Fusion Antibodies PLC

31 July 2020

31 July 2020

Fusion Antibodies plc

("Fusion" or the "Company")

Total Voting Rights

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the issued share capital of the Company at the date of this announcement comprises 25,437,025 ordinary shares of 4 pence each with one voting right per share ('Ordinary Shares'). The Company does not hold any Ordinary Shares in treasury. The total number of Ordinary Shares and voting rights in the Company is therefore 25,437,025.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 Fusion Antibodies plc                                              www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                                       Via Walbrook PR 
 James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                                 Tel: +44 (0)20 3328 
                                                                                        5656 
 James Reeve / Asha Chotai 
 
 Walbrook PR                               Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                                            Mob: +44 (0)7876 741 
                                                                                         001 
 Paul McManus                                                           Mob: +44 (0)7980 541 
                                                                                         893 
 
 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx (TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 100 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotechs get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRBXGDRBGXDGGB

(END) Dow Jones Newswires

July 31, 2020 12:00 ET (16:00 GMT)

Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Fusion Antibodies
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Fusion Antibodies